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Abstract
Cryptococcosis is a life-threatening fungal disease with a high rate of mortality among HIV/AIDS patients across the world.
The ability to penetrate the blood-brain barrier (BBB) is central to the pathogenesis of cryptococcosis, but the way in which
this occurs remains unclear. Here we use both mouse and human brain derived endothelial cells (bEnd3 and hCMEC/D3) to
accurately quantify fungal uptake and survival within brain endothelial cells. Our data indicate that the adherence and
internalisation of cryptococci by brain microvascular endothelial cells is an infrequent event involving small numbers of
cryptococcal yeast cells. Interestingly, this process requires neither active signalling from the fungus nor the presence of the
fungal capsule. Thus entry into brain microvascular endothelial cells is most likely a passive event that occurs following
‘trapping’ within capillary beds of the BBB.
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Introduction
Cryptococcosis is a life-threatening disease caused primarily by
the human fungal pathogen Cryptococcus neoformans. Cryptococcal
infection can potentially occur in any part of the human body
(reviewed in [1]), although central nervous system (CNS)
cryptococcosis accounts for most clinical presentation. Globally,
fatalities due to cryptococcal meningitis were recently estimated at
over 600,000 cases per year of which 504000 (81%) occur in Sub-
Saharan Africa [2]. The victims of cryptococcal infection are
predominantly immunocompromised people infected with C.
neoformans, although there is an increasing incidence of immuno-
competent cryptococcosis caused by C. gattii [3–7]. HIV/AIDS is
the major predisposing condition for cryptococcosis with 10–15%
HIV patients acquiring cryptococcal infection, although prolonged
glucocorticosteroid therapy and solid organ transplantation are
increasingly becoming important [8,9].
The route of cryptococcal infection is believed to be through
inhalation of airborne basidiospores or desiccated yeast cells from
an environmental source to the lungs. The fungal yeast cells may
stay dormant in the host, and can potentially disseminate to all
body organs but there is a high propensity of dissemination to the
brain [10]. Once in the brain the fungus causes meningoenceph-
alitis, a severe form of the disease, which is uniformly fatal if
untreated [11]. Even with the most effective antifungal therapy,
the fatality rate remains high in HIV-associated crytococcosis (10–
25% and .40% in rich and poor settings respectively [12–17]
Dissemination to the brain requires that C. neoformans penetrate the
normally impermeable blood-brain barrier (BBB) [18]. The BBB is
made of microvascular endothelial cells supported by astrocytic
foot processes, pericytes and neuronal processes [19]. Brain
microvascular endothelial cells form strong tight junctions, which
present a formidable barrier to any invading pathogens [18–20].
The mechanism by which C. neoformans penetrates this barrier is
not currently understood, although several possibilities have been
proposed, including passage between neighbouring endothelial
cells (paracellular entry), carriage into the CNS within infected
phagocytes (Trojan Horse model), or uptake by and traversal
through endothelial cells (transcytosis) [21,22]. In the transcellular
model of traversal, adherence to and uptake of cryptococci by
brain microvascular endothelial cells (BMEC) must occur before
transit into the brain. In support of this model, Chang et al used
electron microscopy to demonstrate that cryptococcal yeast cells
could adhere to and become internalised by brain microvascular
endothelial cells [23].
Several pathogen-generated microbial factors including urease,
laccase, capsule and hyaluronic acid have been implicated in
modulating the Cryptococcus – blood-brain barrier interaction
[24,25]. The capsule is a major virulence factor and its role in
pathogen – phagocyte interaction and systemic dissemination of
Cryptococcus is well documented [26]. However, the role of capsule
in regulating CNS invasion remains unclear. Capsule associated
structural changes such as phenotypic switching (rough to smooth)
have been reported to enhance crossing of the blood-brain barrier
[27–31], but a recent study using intravital real time imaging
demonstrated that encapsulated and acapsular strains of C.
neoformans had an equal ability to associate with – and transmigrate
across - the microvascular endothelium into the brain [32].
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Despite these recent advances, however, there are currently no
quantitative data on cryptococcal uptake by brain endothelial cells
in the presence and absence of capsule. Here we report the first
attempts to address this, by using an in vitro brain endothelial cell
culture to quantify association and uptake of cryptococci.
Materials and Methods
Yeast culture
Two sets of isogenic C. neoformans strains, serotype A H99 and its
isogenic acapsular strain cap59 and serotype D B3501 with its
isogenic acapsular strain B4131 were used. Strains were
propagated on YPD agar (1% yeast extract, 1% peptone, 2%
dextrose and 1% agar) at 25uC. Prior to experimentation, cultures
of both strains were grown in YPD broth (1% yeast extract, 1%
peptone and 2% dextrose) at 25uC with rotation at 20 RPM
overnight. The yeast cells were washed with sterile phosphate
buffered saline (PBS) and stained with 0.5 mg/ml FITC for
30 min with shaking (Labrolller, Labnet Inc.) at room tempera-
ture. The required infection inoculum (of 26106 yeast cells) was
determined by counting using a haemocytometer.
Tissue culture
Two types of brain microvascular endothelial cell-lines, the
immortalized mouse brain derived endothelial (bEnd3) cells and
the human brain capillary microvascular endothelial cells
(hCMEC/D3) were used. The bEnd3 cells were grown to
monolayer confluence in 24 well tissue culture plates (Greiner,
UK) containing Dulbecco’s modified Eagle’s medium (DMEM,
Sigma Aldrich) supplemented with 10% foetal bovine serum (FBS),
I% streptomycin/penicillin and 2 mM L-glutamine, 1% non-
essential aminoacids, 1% Sodium pyruvate and 5 mM 2-Mercap-
toethanol. HCMEC/D3 cells were grown in endothelial growth
medium 2 (EGM-2, Lonza, UK) in 24 well tissue culture plates
precoated with Calf Skin collagen (Sigma UK). Seeding plates with
105 endothelial cells per well, ensured even growth of a cell
monolayer. The culture was maintained at 37uC with 5%CO2 for
4–6 days to obtain a fully matured cell monolayer. For
microscopic examination, 13 mm sterile glass coverslips (collagen
coated for hCMEC/D3 cells) were inserted into the 24 well plates
before seeding with endothelial cells, allowing the monolayer to
grow on the coverslip, which could then be easily transferred for
microscopy. Prior to infection, tissue culture growth medium was
replaced with serum free medium and incubated for 1 hr at 37uC.
The cultures were then inoculated with 26106 yeast cells per well,
producing an approximate infection ratio of 1: 3 (target: effector).
Infections were allowed to proceed for either 2 hr or 4 hrs, as
described, at 37uC with 5% CO2. To ensure that the infection
media did not have a negative effect on cryptococcal growth,
cryptococci (105 yeast cells/ml) were directly inoculated into
bEnd3 and or hCMEC/D3 infection medium and growth
recorded over 24 hrs.
Quantification of yeast cell association with, and
internalization by, BMEC cells
The rate of cryptococcal yeast cell association with brain
microvascular endothelial cells (BMEC), bEnd3 and hCMEC/D3
was determined both microscopically and using CFU counts. In
the former, dual colour fluorescence microscopy (Nikon Eclipse Ti
- S, Japan) was used to determine associated (adherent and
internalized) yeast cells. After infection, the non-adherent yeast
cells were removed by washing four times with sterile PBS and the
extracellular adherent yeast cells stained for 10–15 min with
20 mg/ml calcoflour white (adapted from [33]) at room temper-
ature. Since mammalian cells are impermeable to calcofluor white,
internalized yeast retained the green FITC signal while adherent
cells stained blue. Nine random fields per coverslip were viewed
and the internalized and non-internalized yeasts therein counted.
Association (total number of yeast cells –attached or internalized
by BMEC) and internalization were determined and compared to
the original inoculum.
Since this microscopic approach did not distinguish between
live and dead cryptococci, we exploited colony forming unit (CFU)
assays to determine the viability of cryptococci that had been
internalised by cells of the BBB. After removal of non-adherent
cryptococci by extensive washing, endothelial cells were lysed with
200 ml sterile water for 15 min at 37uC to release internalized
cryptococci and the lysate plated on YPD agar for colony counts
(CFU assay). The associated cryptococci were determined as the
ratio of cryptococcal yeast cells (CFU/ml) to the original
inoculum.
Thus, by comparing data derived both from microscopy (which
distinguishes internalised from attached cryptococci, but not live
from dead cells) and from CFU counts (which have the opposite
profile) we were able to accurately estimate both uptake and
survival of cryptococci. The results were recorded as endothelial
cell associated cryptococci per well, which is equivalent to
cryptococci per coverslip for microscopy and CFU/ml for colony
counts.
Opsonisation
Antibodies to Cryptococcus have been reported to exist in
circulation as early as childhood [34]. Furthermore, phagocytosis
studies using macrophages have shown that internalization of
cryptococcal yeast cells is enhanced by antibody and or
complement mediated opsonisation [35–37]. However, no studies
have investigated whether adherence and uptake of cryptococci by
BMEC requires opsonisation. To address this, opsonised and non-
oposonized live and heat killed H99 cryptococci were incubated
with BMEC for 2 hr and 4 hr at 37uC. Opsonisation was done by
adding 5 mg/ml the capsule specific 18B7 mouse IgG (a kind gift
from Arturo Casadevall) to 200 ml aliquot of yeast cells and rotated
(Labroller, Labnet Inc, US) at room temperature for 30 min prior
to infection. The rate of association and internalization was
determined as described above.
Role of viability in Cryptococcus – BMEC association and
internalization
We tested whether dead cryptococci adhere and are internal-
ized by BMEC at the same rate as live cells. 1 ml aliquots of both
encapsulated and non-capsulated cryptococci were heated at 65uC
for 15 min prior to infection. Adherent and internalized yeasts
were determined microscopically. To determine if the yeast
culture was completely killed, 20 ml aliquots were plated on YPD
agar and no growth was observed.
Fixed endothelial cell control
As a negative control, mature endothelial cell (bEnd3 and
hCMEC/D3) monolayers were fixed with 250 ml PFA 4% in PBS
for 10 min at room temperature, rinsed five times with PBS and
then inoculated with 26106 cryptococci per ml. As for the live
endothelial cell monolayers, the fixed monolayers were incubated
with cryptococci for 2 hr and 4 hr at 37uC with 5% CO2 and
washed four times to remove non-adherent yeast cells. 200 ml
sterile water was used to lyse the endothelial cells with additional
scraping to remove any remaining endothelial cell associated
Cryptococcal Uptake by BMEC
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cryptococci. The lysate was plated on YPD agar at 25uC and
colony counts were made after 48 hr.
Statistical analysis
Non-parametric Mann-Whitney U Test and Wilcoxon Signed
Ranks Test were used to measure the significance of adherence at
different conditions and time points. Mann-Whitney U Test was
applied to compare the means of test different setups, for instance
comparing the mean association of encapsulated and acapsular
strain to bEnd3 and or hCMEC/D3 cells. Wilcoxon Signed ranks
test was applied to compare means of the same setup at different
time points, for example comparing the mean association of
encapsulated H99 strain or the acapsular mutant with endothelial
cells after 2 hrs and 4 hrs of incubation at 37uC.
Results
Cryptococcal association with and internalization by the
murine brain endothelial cell line bEnd3
We exposed the mouse brain endothelial cell line bEnd3 to
wildtype C. neoformans H99 and its isogenic acapsular derivative,
cap59 [38]. The two strains were tested for their rate of binding
and internalization by BMEC and whether the presence or
absence of capsule has an effect on this interaction. After two
hours of exposure to bEnd3 cells at 37uC, 8.86103 (0.43%) of
inoculated wild type (H99) cryptococci had adhered strongly to the
endothelial layer, rising to 2.06104 (1.2%) after four hours.
Similarly, 1.66104 (0.8%) of the acapsular cryptococci had
associated with bEnd3 cells at 2 hr rising to 2.56104 (1.23%)
after four hours of incubation at 37uC (Figure 1A). In contrast,
binding to paraformaldehyde-fixed BMEC monolayers was
negligible at all time points tested (Figure S1). By using calcoflour
staining to discriminate surface bound from internalised crypto-
cocci, we determined that 3.16103 (35% of associated) and
4.46103 (28% of associated) wild type and acapsular cryptococci,
respectively, had been internalised by 2 hours at 37uC, rising to
8.16103 (40%) and 8.66103 (35%) respectively by 4 hrs
(Figure 1B). Importantly, for both strains, microscopic yeast cell
counts and live CFU counts gave the same rate of association for
both H99 and cap59, suggesting that there is no significant drop in
cryptococcal viability upon adherence to or uptake by bEnd3 cells.
Effect of opsonisation on Cryptococcus – BMEC
association and internalization
Since most individuals produce circulating antibodies to
cryptococci by late childhood [34], we investigated whether
opsonisation of cryptococci with antibody increases the association
and internalization with brain endothelial cells. However, there
were no significant differences between opsonised and non-
opsonised yeast in either adherence or uptake at either time point
tested (Figure 2A and B), suggesting binding and uptake by brain
endothelial cells is opsonin independent.
Cryptococcal association and internalization by human
brain endothelial cells, hCMEC/D3
To test whether the rates of adherence and uptake that we had
observed in bEnd3 cells were species specific, we repeated our
analyses using the human brain endothelial derived cell-line,
hCMEC/D3. As with bEnd3 cells, both microscopic and CFU
counts showed that encapsulated H99 and its isogenic acapsular
mutant cap59 associated and were engulfed at the same rate,
P =.0.05 at 2 hr and 4 hr of infection respectively (Figure 3A and
B). To determine whether the interaction varies from strain to
strain, we tested a different pair of C. neoformans serotype D strains;
encapsulated B3501 and its isogenic acapsular strain B4131. Like
the H99/cap59 isogenic pair, both B3501 and B4131 strains
associated and were internalized at the same rate with hCMEC/
D3 cells (Figure 4A and B).
However, unlike bEnd3 cells, we observed a significant decrease
over time in cryptococcal CFU counts for both strains.
Microscopic counts revealed that association and internalization
for both strains increases with time of incubation, suggesting a loss
of viability by cryptococci during association with hCMEC/D3
cells (Figure 3A and 4A). One potential explanation for this result
is that hCMEC/D3 cells may generate a more antimicrobial
environment for cryptococci following uptake than that produced
by bEnd3 cells. Thus bEnd3 cells and hCMEC/D3 cells bind and
engulf cryptococci at similar rates, but only hCMEC/D3 cells are
able to significantly reduce cryptococcal viability following uptake.
Viability of cryptococci is not a prerequisite for
association and internalization by BMEC
Lastly, we investigated whether the uptake of cryptococci into
BMEC requires active signals from the pathogen. However, heat-
killed H99 retained the ability to bind and enter both mouse
bEnd3 and human hCMEC/D3 cells at a similar rate to live yeast
(Figure 5A and C). Although viable cryptococci showed higher
association efficiency in bEnd3 cells, there was no significant
difference between internalization of viable and heat-killed
cryptococci in both bEnd3 and hCMEC/D3 cells. (Figure 5B
and D), suggesting that uptake is a passive process that occurs
independently of yeast cell viability.
Discussion
The mechanism by which C. neoformans associates with – and
penetrates - the BBB remains a critical question in understanding
the pathogenesis of CNS cryptococcosis. Considerable evidence
shows that the penetration of the BBB by C. neoformans may occur
via infected phagocytes [21,39] or transcellularly through
adherence and phagocytosis by the brain microvascular endothe-
lial cells [22,32]. Determining the relative contribution of these
different routes to CNS cryptococcosis requires quantitative
analysis of the interaction between cryptococci and brain
microvascular cells, data that are currently lacking. Here we take
the first steps to address this shortfall by using both mouse and
human brain endothelial cell models.
Our data indicate that cryptococcal association with brain
microvascular endothelial cells is a relatively infrequent event,
although one that increases with extended periods of incubation.
In both cell lines, mouse and human, less than 2% of encapsulated
and acapsular cryptococci were strongly bound by 4 hrs of
incubation. However, once bound, the probability of being
internalized is high (typically .40% within four hours). These
findings support recent observations in a mouse cryptococcosis
model, which suggest that transmission across the BBB is a non-
specific event dependent on trapping of cryptococci in narrow
brain capillaries followed by phagocytosis into brain microvascular
endothelial cells [32]. This implies that the adherence to – and
phagocytosis of - cryptococci by BMEC is a slow process involving
single cryptococci binding at any one time. We thus hypothesize
that cryptococcal meningoencephalitis may be the result of a very
small number of cryptococcal cells penetrating the BBB and
subsequently proliferating to high numbers within the brain tissue.
If so, then clinical approaches that reduce cryptococcal binding to
endothelia even marginally may result in significant improvements
to patient health. On the other hand, the low transcellular uptake
Cryptococcal Uptake by BMEC
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35455
suggests that C. neoformans might engage multiple entry mecha-
nisms into the brain.
Possession of a capsule is a major virulence factor in C.
neoformans and the presence of a capsule modulates many aspects of
the interaction between cryptococci and infected hosts [40,41].
Cryptococcus – endothelial cell interaction studies have yielded
conflicting results regarding how capsule impacts on cryptococcal
binding and uptake by BMEC [27,29–31,42]. By studying isogenic
pairs of wild type and acapsular cryptococci and different brain
endothelial cell-lines, we have shown that binding and uptake of
cryptococci by BMEC is capsule independent. In agreement with
this finding, intravital imaging of cryptococcal traversal of the
Figure 1. Binding and uptake of H99 and cap59 to the murine brain endothelial cell line, bEnd3. BEnd3 cells were exposed to wild type
H99 and its acapsular derivative cap59 for 2 hr and 4 hr at 37uC. (A) The rate of association (bound and internalized cryptococci) was determined
both by microscopy and live CFU counts. The rate of association increased significantly in a time dependent manner, (P,0.01 for both strains).
However, there was no difference in association of encapsulated H99 or acapsular cap59 cells (P = 0.1 and 0.5 at 2 hr and 4 hr respectively). (B)
Internalization of the two strains, H99 and cap59 by bEnd3 cells as determined by fluorescence microscopy. Internalized cryptococci (pre-stained with
FITC) were distinguished from extracellular adherent ones by counter labelling with calcofluor white after infection. Intracellular cryptococci retained
the FITC green signal while extracellular cells acquired the blue signal from calcofluor. The number of phagocytosed cryptococci increased
significantly in a time dependent manner, (P,0.01 for both strains). However, there was no difference in internalization of encapsulated H99 and
acapsular cap59, (P = 0.5 and 0.8 at 2 hr and 4 hr respectively). Error bars are standard error of the mean, n = 5 repeats.
doi:10.1371/journal.pone.0035455.g001
Figure 2. Effect of opsonisation on cryptococcal binding and uptake by bEnd3 cells. Live (LV) and heat-killed (HK) H99 cryptococci were
opsonised with mouse derived anti-capsule IgG antibody, 18B7 and the rate of adherence and internalization was determined by fluorescence
microscopy. (A) Association of opsonised (op) and non-opsonised (Nop) cryptococci with bEnd3 cells. Rate of association of opsonised and non-
opsonised H99LV cryptococci was similar, P = 0.8 and 0.4 at 2 hr and 4 hr respectively. Similarly, there was no difference between opsonised and non-
opsonised heat-killed H99 cryptococci, P = 0.9 and 0.5 at 2 hr and 4 hr respectively. (B) Rate of internalization of opsonised and non-opsonised
cryptococci internalized by bEnd3 cells. The number of internalized H99LV cryptococci was similar, regardless of opsonisation status (P = 0.9 at both
2 hr and 4 hr). Similarly, there was no difference between opsonised and non-opsonised heat-killed H99 cryptococci, P = 0.5 and 0.4 at 2 hr and 4 hr
respectively. Error bars are standard error of the mean, n = 5 repeats.
doi:10.1371/journal.pone.0035455.g002
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blood-brain barrier has demonstrated equivalent crossing of the
blood-brain barrier by wild type and acapsular cryptococcal yeast
cells [32], an observation that implies the dispensability of the
capsule for cryptococcal penetration of the blood-brain barrier.
Our finding that neither opsonisation nor active signalling from
the cryptococcal cell are required for uptake are in line with recent
data suggesting that cryptococcal uptake into brain endothelia is
mediated by binding of endothelial CD44 to hyaluronic acid on
Figure 3. Binding and uptake of H99 and cap59 with human brain endothelial cell line, hCMEC/D3. Like bEnd3 cells, hCMEC/D3 cells
were exposed to the C. neoformans serotype A isogenic strains, wild type H99 and acapsular derivative cap59 for 2 hr and 4 hr at 37uC. Microscopic
(Mic.) and live CFU counts were performed to determine the association and survival of cryptococci. (A) Association efficiency of H99 and cap59
cryptococci with hCMEC/D3 cells. As opposed to microscopic counts, live CFU counts showed a time dependent decrease in the number of
associated cryptococci by 4 hr of incubation, w=P,0.05 and ww=P,0.01 for H99 and cap59 respectively, suggesting a drop in viability of the
hCMEC/D3 associated H99 and cap59 cryptococci. There was no difference in association of encapsulated H99 and acapsular cap59, P = 0.7 and 0.6 at
2 hr and 4 hr respectively. (B) Internalization of encapsulated H99 and acapsular cap59 cryptococci by human brain endothelial cell line, hCMEC/D3
cells. The internalized cryptococci and extracellular adherent were determined as in Figure 1. As with association, the number of phagocytosed
cryptococci increased significantly in a time dependent manner, P = 0.01 and,0.01 for H99 and cap59 respectively. However, there was no difference
in internalization of H99 and acapsular cap59 cryptococci, P = 0.5 and 0.8 at 2 hr and 4 hr respectively. Error bars are standard error of the mean, n = 6
repeats.
doi:10.1371/journal.pone.0035455.g003
Figure 4. Binding and uptake of B3501 and B-4131 with human brain endothelial cell line, hCMEC/D3. HCMEC/D3 cells were exposed to
C. neoformans serotype D wild type B3501 and its isogenic acapsular mutant B4131 for 2 hr and 4 hr at 37uC. Microscopic and live CFU counts were
performed to determine the association and survival of cryptococci. (A) Association efficiency of B3501 and B4131 cryptococci with hCMEC/D3 cells.
Like the H99-cap59 pair, live CFU counts showed a time dependent decrease in the number of associated cryptococci by 4 hr of incubation,
w=P,0.01, ww=P,0.01 for both B3501 and B4131. There was no difference in association by encapsulated B3501 and acapsular B4131, P-
value =.0.05 at 2 hr of incubation. However, B4131 was significantly more associated, P = 0.02 (Microscopy) and ,0.01 (CFU) by 4 hr of incubation.
(B) Internalization of encapsulated B3501 and its acapsular mutant derivative B4131 by hCMEC/D3 cells determined by fluorescence microscopy (Mic).
The number of phagocytosed cryptococci increased significantly in a time dependent manner, P = 0.01 for both strains. However, there was no
difference in internalization of B3501 and B4131, P = 0.5 and 0.2 at 2 hr and 4 hr respectively. Error bars are standard error of the mean, n = 6 repeats.
doi:10.1371/journal.pone.0035455.g004
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the yeast surface [25]. Heat killing of the yeast is unlikely to disrupt
this interaction. Although viable and non-viable (heat-killed) are
equally internalized (this study), the non-viable cryptococci are
unlikely to survive lysosomal degradation and hence may not
transmigrate across the BBB in vivo [32]. Interestingly, however,
our data suggest that human derived endothelia (but not murine
bEnd3 cells) may be capable of killing intracellular cryptococci.
Presumably crossing the BBB intact thus requires one or more of
the virulence factors used by cryptococci to resist phagosomal
killing [43], explaining why heat-killed cryptococci can enter
endothelial cells but are not seen to transmigrate.
Supporting Information
Figure S1 Binding to fixed endothelial cell monolayers
(negative control). To verify that the observed binding
occurred in association with endothelial cells, and not due to
indirect sequestration of yeast cells, bEnd3 and hCMEC/D3
monolayers were killed by paraformaldehyde fixation prior to
cryptococci inoculation. For all conditions, cryptococcal binding
was reduced by between one and two log orders, indicating that
that viable endothelial cells were responsible for the observed
cryptococcal association.
(TIF)
Acknowledgments
We gratefully acknowledge the help of Teun Boekhout, Joseph Heitman,
Mark Gambleton and Jane McKeating in providing yeast strains and
mammalian cell lines used in this work. The 18B7 antibody was a kind gift
from Arturo Casadevall.
Author Contributions
Conceived and designed the experiments: WS RCM. Performed the
experiments: WS. Analyzed the data: WS RCM. Contributed reagents/
materials/analysis tools: WS RCM. Wrote the paper: WS.
References
1. Lin X (2009) Cryptococcus neoformans: Morphogenesis, infection, and evolution.
Infect Genet Evol 9(4): 401–416.
2. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009)
Estimation of the current global burden of cryptococcal meningitis among
persons living with HIV/AIDS. AIDS 23(4): 525–530.
Figure 5. Effect of viability on binding and phagocytosis of H99 and cap59 strains by BMEC. Heating for 15 min at 65uC prior to infection
killed H99 and cap59 cryptococci. Brain microvascular cells (BMEC), bEnd3 and or hCMEC/D3 cells were exposed in parallel to live (LV) and heat-killed
(HK) cryptococci for 2 hr and 4 hr at 37uC and the number of bound and internalized cryptococci was determined by fluorescence microscopy. (A and
C) Association efficiency of live and heat-killed H99 or cap59 cryptococci by bEnd3 and hCMEC/D3 cell respectively. There was no difference in
association of viable H99 and cap59 cryptococci with hCMEC/D3 cells at either time point, P.0.05. However, viable cryptococci were more associated
than non-viable ones by 4 hr of incubation in bEnd3 cells, P,0.01 for both H99 and cap59 respectively. (B and D) Internalization efficiency of LV and
HK H99 and cap59 cryptococci by bEnd3 and hCMEC/D3 cells. Both live and heat-killed cryptococci showed a time dependent increase in
phagocytosis by both bEnd3 and hCMEC/D3 cells, however the rate of phagocytosis did not vary between the viable and non-viable cryptococci in
both cell-lines, P.0.05 at both 2 hr and 4 hr of incubation. Error bars are standard error of the mean, n = 5 repeats.
doi:10.1371/journal.pone.0035455.g005
Cryptococcal Uptake by BMEC
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e35455
3. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, et al. (2004) A rare
genotype of Cryptococcus gattii caused the cryptococcosis outbreak on vancouver
island (british columbia, canada). Proc Natl Acad Sci U S A 101(49):
17258–17263.
4. Byrnes EJ 3rd, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, et al. (2009)
Molecular evidence that the range of the Vancouver island outbreak of
cryptococcus gattii infection has expanded into the pacific northwest in the
united states. J Infect Dis 199(7): 1081–1086.
5. Byrnes EJ 3rd, Li W, Lewit Y, Ma H, Voelz K, et al. (2010) Emergence and
pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest
united states. PLoS Pathog 6(4): e1000850.
6. Byrnes EJ, Heitman J (2009) Cryptococcus gattii outbreak expands into the
northwestern united states with fatal consequences. F1000 Biol Rep 1: 62.
7. Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, et al. (2009) Spread of
Cryptococcus gattii into pacific northwest region of the united states. Emerging
Infect Dis 15(8): 1185–1191.
8. Neofytos D, Fishman JA, Horn D, Anaissie E, Chang CH, et al. (2010)
Epidemiology and outcome of invasive fungal infections in solid organ transplant
recipients. Transpl Infect Dis 12(3): 220–229.
9. Mitchell TG, Perfect JR (1995) Cryptococcosis in the era of AIDS–100 years
after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8(4): 515–548.
10. Huffnagle GB, McNeil LK (1999) Dissemination of C. neoformans to the central
nervous system: Role of chemokines, Th1 immunity and leukocyte recruitment.
J Neurovirol 5(1): 76–81.
11. Casadevall A, Perfect JR, eds (1998) Cryptococcus neoformans. Washington, DC:
American Society for Microbiology. 541 p.
12. Lortholary O (2007) Management of cryptococcal meningitis in AIDS: The
need for specific studies in developing countries. Clin Infect Dis 45(1): 81–83.
13. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, et al. (2010)
Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is
associated with subsequent immune reconstitution inflammatory syndrome.
J Infect Dis 202(6): 962–970.
14. Nussbaum JC, Jackson A, Namarika D, Phulusa J, Kenala J, et al. (2010)
Combination flucytosine and high-dose fluconazole compared with fluconazole
monotherapy for the treatment of cryptococcal meningitis: A randomized trial in
malawi. Clin Infect Dis 50(3): 338–344.
15. Kambugu A, Meya DB, Rhein J, O’Brien M, Janoff EN, et al. (2008) Outcomes
of cryptococcal meningitis in Uganda before and after the availability of highly
active antiretroviral therapy. Clin Infect Dis 46(11): 1694–1701.
16. Bicanic T, Harrison TS (2005) Cryptococcal meningitis. Br Med Bull 72:
99–118.
17. Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, et al. (2001) Clinical
presentation, natural history, and cumulative death rates of 230 adults with
primary cryptococcal meningitis in zambian AIDS patients treated under local
conditions. Postgrad Med J. pp 769–73.
18. Kim KS (2008) Mechanisms of microbial traversal of the blood-brain barrier.
Nat Rev Microbiol 6(8): 625–634.
19. Brown RC, Morris AP, O’Neil RG (2007) Tight junction protein expression and
barrier properties of immortalized mouse brain microvessel endothelial cells.
Brain Res 1130(1): 17–30.
20. Correale J, Villa A (2009) Cellular elements of the blood-brain barrier.
Neurochem Res.
21. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, et al. (2009) Evidence of
a role for monocytes in dissemination and brain invasion by Cryptococcus
neoformans. Infect Immun 77(1): 120–127.
22. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, et al. (2004)
Cryptococcal yeast cells invade the central nervous system via transcellular
penetration of the blood-brain barrier. Infect Immun 72(9): 4985–4995.
23. Chang YC, Stins MF, McCaffery MJ, Miller GF, Pare DR, et al. (2004)
Cryptococcal yeast cells invade the central nervous system via transcellular
penetration of the blood-brain barrier. Infect Immun 72(9): 4985–4995.
24. Eisenman HC, Casadevall A, McClelland EE (2007) New insights on the
pathogenesis of invasive Cryptococcus neoformans infection. Curr Infect Dis Rep
9(6): 457–464.
25. Huang SH, Long M, Wu CH, Kwon-Chung KJ, Chang YC, et al. (2011)
Invasion of Cryptococcus neoformans into human brain microvascular endothelial
cells is mediated through the lipid rafts-endocytic pathway via the dual specificity
tyrosine phosphorylation-regulated kinase 3 (DYRK3). J Biol Chem 286(40):
34761–34769.
26. Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A () Cryptococcus:
From human pathogen to model yeast. Washington, DC.: ASM Press.
27. Fries BC, Taborda CP, Serfass E, Casadevall A (2001) Phenotypic switching of
Cryptococcus neoformans occurs in vivo and influences the outcome of infection.
J Clin Invest 108(11): 1639–1648.
28. Chen SH, Stins MF, Huang SH, Chen YH, Kwon-Chung K, et al. (2003)
Cryptococcus neoformans induces alterations in the cytoskeleton of human brain
microvascular endothelial cells. J Med Microbiol 52: 961–970.
29. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, et al. (2005)
Capsule structure changes associated with Cryptococcus neoformans crossing of the
blood-brain barrier. Am J Pathol 166(2): 421–432.
30. Guerrero A, Jain N, Goldman DL, Fries BC (2006) Phenotypic switching in
Cryptococcus neoformans. Microbiology 152: 3–9.
31. Jain N, Guerrero A, Fries BC (2006) Phenotypic switching and its implications
for the pathogenesis of Cryptococcus neoformans. FEMS Yeast Res 6(4): 480–488.
32. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, et al. (2010) Real-time imaging of
trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse
brain. J Clin Invest 120(5): 1683–1693.
33. Jong AY, Stins MF, Huang SH, Chen SH, Kim KS (2001) Traversal of Candida
albicans across human blood-brain barrier in vitro. Infect Immun 69(7):
4536–4544.
34. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, et al. (2001)
Serologic evidence for Cryptococcus neoformans infection in early childhood.
Pediatrics 107(5): E66.
35. Mukherjee S, Lee SC, Casadevall A (1995) Antibodies to Cryptococcus neoformans
glucuronoxylomannan enhance antifungal activity of murine macrophages.
Infect Immun 63(2): 573–579.
36. Vecchiarelli A, Pietrella D, Bistoni F, Kozel TR, Casadevall A (2002) Antibody
to Cryptococcus neoformans capsular glucuronoxylomannan promotes expression of
interleukin-12Rbeta2 subunit on human T cells in vitro through effects mediated
by antigen-presenting cells. Immunology 106(2): 267–272.
37. Bolanos B, Mitchell TG (1989) Phagocytosis and killing of Cryptococcus neoformans
by rat alveolar macrophages in the absence of serum. J Leukoc Biol 46(6):
521–528.
38. De Jesus M, Chow SK, Cordero RJ, Frases S, Casadevall A (2010)
Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii
are structurally and antigenically variable. Eukaryot Cell 9(7): 1018–1028.
39. Santangelo R, Zoellner H, Sorrell T, Wilson C, Donald C, et al. (2004) Role of
extracellular phospholipases and mononuclear phagocytes in dissemination of
cryptococcosis in a murine model. Infect Immun 72(4): 2229–2239.
40. Syme RM, Bruno TF, Kozel TR, Mody CH (1999) The capsule of Cryptococcus
neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which
can be restored with anticapsular antibody. Infect Immun 67(9): 4620–4627.
41. Zaragoza O, Chrisman CJ, Castelli MV, Frases S, Cuenca-Estrella M, et al.
(2008) Capsule enlargement in Cryptococcus neoformans confers resistance to
oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol
10(10): 2043–2057.
42. Ibrahim AS, Filler SG, Alcouloumre MS, Kozel TR, Edwards JE, et al. (1995)
Adherence to and damage of endothelial cells by Cryptococcus neoformans in vitro:
Role of the capsule. Infect Immun 63(11): 4368–4374.
43. Ma H, May RC (2009) Virulence in Cryptococcus species. Adv Appl Microbiol 67:
131–190.
Cryptococcal Uptake by BMEC
PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35455
